Prelude Therapeutics (PRLD) Total Non-Current Liabilities (2019 - 2026)

Prelude Therapeutics has disclosed Total Non-Current Liabilities across 8 years of filings, most recently posting $56.7 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $56.7 million, up 61.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $56.7 million (up 61.69% YoY), and the FY2025 annual result was $69.8 million, up 70.48% from the prior year.
• Total Non-Current Liabilities came in at $56.7 million for Q1 2026 at Prelude Therapeutics, down from $69.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $69.8 million in Q4 2025 to a low of $15.2 million in Q2 2023.
• The 5-year median for Total Non-Current Liabilities is $33.3 million (2025), against an average of $32.1 million.
• Across the five-year window, Total Non-Current Liabilities decreased 21.65% in 2023 and jumped 155.43% in 2024, its largest moves.
• Prelude Therapeutics' Total Non-Current Liabilities stood at $21.7 million in 2022, then jumped by 71.58% to $37.2 million in 2023, then increased by 10.02% to $41.0 million in 2024, then soared by 70.48% to $69.8 million in 2025, then slipped by 18.84% to $56.7 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $56.7 million (Q1 2026), $69.8 million (Q4 2025), and $33.3 million (Q3 2025), per Business Quant data.